South Korea has received an emergency authorization for Pfizer Inc.'s oral medicine to treat Covid-19 on Monday, making it the country's first usage of such a medication.

According to Pfizer and the South Korean Ministry of Food and Drug Safety, Paxlovid is an antiviral tablet for the treatment of mild to moderate Covid-19 in patients at high risk of hospitalisation or death.

According to sources, the Ministry organised a team of specialists from both inside and outside to assess Paxlovid's safety and efficacy and came to the conclusion that the oral pill is required to address the public health crisis.   The medication is a protease inhibitor antiviral therapy that is designed to be taken orally and can be provided at the first indication of infection or awareness of an exposure.

According to the Ministry, Paxlovid minimises the risk of hospitalisation or death in individuals who are at high risk of serious illness. Adults and children patients 12 years of age and older who are at high risk of progressing to severe instances will be prescribed the tablet. Paxlovid should be started as soon as possible after a diagnosis of Covid-19, and it should be taken twice a day for five days.

Pfizer's first oral pill to treat Covid-19 is approved by USFDA

Oxford, AstraZeneca developing Omicron-targeted variant of vaccine

Israeli Govt announces fourth booster dose to fight Omicron